Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 29

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 29
---
holders.

On December 21, 2023, we completed
the closing of an underwritten public offering, pursuant to which we issued and sold (i) 4,355 Class A units, or Class A Units, at a
public offering price of $500.00 per Class A Unit, with each Class A Unit consisting of (a) one Depositary Share, (b) one Series E Warrant,
and (c) one Series F Warrant, and (ii) 7,644 Class B units, or Class B Units, at a public offering price of $269.999 per Class B Unit,
with each Class B Unit consisting of (a) one pre-funded warrant, exercisable for one Depositary Share, (b) one Series E Warrant,
and (c) one Series F Warrant. The aggregate gross proceeds to the Company were approximately $6.0 million. Additionally, we issued warrants
to purchase 480 of our Depositary Shares in connection with the offering to the underwriter, or the December 2023 Underwriter Warrants.

On February 26, 2024, in connection
with our Company’s obligations under a license agreement with Melior, we issued 1,417 Depositary Shares to Bukwang Pharmaceutical
Co. Ltd., or Bukwang.

On April 29, 2024, in connection with
the closing of a license agreement, we issued 1,512 Depositary Shares to Emtora.

On May 24, 2024, in connection with
the transactions contemplated by certain warrant inducement letters, or the Warrant Agreements, we issued an aggregate of 12,417 Depositary
Shares to certain holders of our Series E Warrants and Series F Warrants, upon the exercise of 6,290 Series E Warrants and 6,127 Series
F Warrants, at an exercise price of $375.00 per share. In addition, we issued to such holders an aggregate of 9,434 Series G warrants,
or the Series G Warrants, and 14,780 Series H Warrants. The aggregate gross proceeds to the Company were approximately $6.05 million,
before deducting agent fees and expenses. Additionally, we issued warrants to purchase 644 of our Depositary Shares in connection with
the offering to the warrant agent and certain of their designees, or Warrant Agent Warrants.

Between December 21, 2023 and June
30, 2025, we have